{{ currentBoardShortName }}
  • Markets
  • Indices
  • Currencies
  • Energy
  • Metals
Markets
As of: {{timeStamp.date}}
{{timeStamp.time}}

Markets

{{ currentBoardShortName }}
  • Markets
  • Indices
  • Currencies
  • Energy
  • Metals
{{data.symbol | reutersRICLabelFormat:group.RICS}}
 
{{data.netChng | number: 4 }}
{{data.netChng | number: 2 }}
{{data | displayCurrencySymbol}} {{data.price | number: 4 }}
{{data.price | number: 2 }}
{{data.symbol | reutersRICLabelFormat:group.RICS}}
 
{{data.netChng | number: 4 }}
{{data.netChng | number: 2 }}
{{data | displayCurrencySymbol}} {{data.price | number: 4 }}
{{data.price | number: 2 }}

Latest Videos

{{ currentStream.Name }}

Related Video

Continuous Play:
ON OFF

The information you requested is not available at this time, please check back again soon.

More Video

Jan 5, 2018

Aurora Cannabis buys more CanniMed shares, upping stake to 2.7%

Aurora Cannabis facility in Montreal Nov. 24, 2017

Security Not Found

The stock symbol {{StockChart.Ric}} does not exist

See Full Stock Page »

CALGARY - Aurora Cannabis Inc. (ACB.TO) says it has increased its stake in competitor CanniMed Therapeutics Inc. (CMED.TO) by buying 91,800 common shares, taking its total to 657,800 or about 2.7 per cent of the outstanding share pool.

Edmonton-based Aurora says its purchases were made in connection with its offer in November to purchase all of the common shares of CanniMed, a takeover that has been aggressively resisted by the target company.

It says the highest price paid for CanniMed shares on Thursday was $23.99 and it has paid an average price of $22.98 per share in the three purchases of its campaign starting last Friday.

Aurora has said it's allowed to buy up to about five per cent of the Saskatoon-headquartered CanniMed's stock on the open market.
On Wednesday, CanniMed urged shareholders not to sell, arguing Aurora's hostile proposed all-stock deal has had a detrimental effect on its share price.